



ASX ANNOUNCEMENT

10th June 2025

OUTCOME OF STRATEGIC REVIEW

Highlights:

- **Focus on Technology:**
OPL is committed to building out its technology to create a world-leading AI platform.
- **Enhancing AI Capabilities:**
Improve the AI model by advancing self-learning functionality, integrating more data, increasing processing speed, expanding capabilities, and improving accuracy.
- **Complementary Applications:**
Investigate opportunities to leverage OPL's powerful AI platform, dataset and know-how for broader application.
- **Strategic Collaboration & Acquisition:**
Identify collaboration and acquisition opportunities to strengthen OPL's AI infrastructure and expand access to data for AI training.
- **Leveraging Proprietary Data:**
Leverage proprietary dataset comprising over 520,000 biotech trial records and 780,000 million data points to mitigate failure and regulatory risks, fast-track clinical development, and significantly reduce costs.
- **Board and Management Enhancements:**
Key hires at the board and management levels to enhance capabilities.

Opyl Limited ("**OPL**" or "the **Company**") is pleased to announce the following outcomes of a Strategic Review process.

Board and Management Update:

The Board has concluded its strategic review and as part of this process, it will be implementing targeted changes to boost expertise in AI and data-driven pharmaceutical



innovation. In line with our commitment to continuous improvement, the Board is assessing both board composition and senior management roles to ensure the right leadership is in place for executing our enhanced strategic priorities. Details of these appointments and changes will be communicated in due course.

These strategic initiatives are designed to position OPL as a vertically integrated leader in AI drug development and clinical trial process, ensuring robust platform capabilities and sustained long-term growth.

Business Strategy:

The Company's renewed strategy centres on the following 5 objectives:

1. AI Model and Technology Development:

Focus on building a world-leading AI drug discovery platform by further developing our technological capabilities. Improve the AI model's self-learning functionalities, increase data integration, boost operational speed, expand overall functionality, and deliver highly accurate outcomes.

2. Collaboration and Acquisition:

OPL is actively evaluating strategic collaboration and acquisition opportunities aimed at fortifying its AI infrastructure and widening its data access channels for enhanced AI training.

3. Identify Complementary Applications:

The Company is investigating several opportunities to expand the application of its AI platform beyond biotech trials. The demand for cutting-edge AI solutions across sectors is immense and OPL can harness its platform and expertise to benefit from the AI era.

4. Securing Commercial Arrangements:

Establish commercial arrangements that deliver immediate product enhancements and position the Company for multiple significant revenue streams in the near term.



5. **Data Leverage:**

OPL is uniquely positioned globally with its expansive proprietary dataset of 520,000+ biotech trials and 780 million data points. The Company remains dedicated to significantly improving drug development success rates, minimising regulatory and operational risks, accelerating clinical development timelines, and reducing the soaring costs of trials.

With more data comes smarter AI. OPL already analyses over 1,500 structured and unstructured variables and instantly simulates trial designs up to 100,000 times per trial, all enhanced through GPT-4 integration, to forecast clinical trial outcomes. This is already world leading and the team is excited about what is achievable with more data and enriched AI infrastructure.

6. **Leadership Enhancements:**

Deploy key hires at both the board and management levels, bringing critical expertise in AI, data analytics, and strategic execution.

Corporate Advisor:

OPL has appointed Sandton Capital Advisory to advise and assist the Board in the execution of the strategic review outcomes. With an extensive background in technology ventures and AI innovation, Sandton will be instrumental in ensuring that the Company's strategic imperatives—particularly in the areas of AI technology development, data infrastructure, and commercial arrangements—are successfully implemented.

Mr Saurabh Jain, Executive Chair of OPL, commented:

"The completion of this strategic review and recent successful capital raise marks a turning point for OPL. Our renewed focus on AI-driven drug discovery is not merely about enhancing shareholder value—it's about redefining what is possible for human health. For example, it is estimated that over 7,000 rare diseases affect nearly 400 million people globally, with an



estimated 95% of these conditions lacking approved treatment options¹.

I believe that the most exciting outcome of the AI revolution lies in health, where its power can save and improve lives by uncovering new treatments and transforming clinical outcomes. At the same time, we have an opportunity to harness our cutting-edge technology, proprietary data and extensive expertise to push the boundaries of the AI revolution."

This announcement has been authorised for release by the Board

-ENDS-

For investor enquiries:

Saurabh Jain
Executive Chair
Email: saurabh@trialkey.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.

¹ Chiesi Rare Diseases – Rare disease burden of care and the economic impact on citizens in Germany, France and Italy. Available at: Chiesi Rare Diseases Report.